Literature DB >> 24843166

Removing T-cell epitopes with computational protein design.

Chris King1, Esteban N Garza2, Ronit Mazor3, Jonathan L Linehan4, Ira Pastan3, Marion Pepper2, David Baker5.   

Abstract

Immune responses can make protein therapeutics ineffective or even dangerous. We describe a general computational protein design method for reducing immunogenicity by eliminating known and predicted T-cell epitopes and maximizing the content of human peptide sequences without disrupting protein structure and function. We show that the method recapitulates previous experimental results on immunogenicity reduction, and we use it to disrupt T-cell epitopes in GFP and Pseudomonas exotoxin A without disrupting function.

Entities:  

Keywords:  Rosetta; biotherapeutics; deimmunization; immunotoxin; machine learning

Mesh:

Substances:

Year:  2014        PMID: 24843166      PMCID: PMC4060723          DOI: 10.1073/pnas.1321126111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   12.779


  32 in total

Review 1.  MHC class II epitope predictive algorithms.

Authors:  Morten Nielsen; Ole Lund; Søren Buus; Claus Lundegaard
Journal:  Immunology       Date:  2010-04-12       Impact factor: 7.397

2.  Automating human intuition for protein design.

Authors:  Lucas G Nivón; Sinisa Bjelic; Chris King; David Baker
Journal:  Proteins       Date:  2013-11-22

3.  Use of the green fluorescent protein as a marker to identify and track genetically modified hematopoietic cells.

Authors:  D A Persons; J A Allay; J M Riberdy; R P Wersto; R E Donahue; B P Sorrentino; A W Nienhuis
Journal:  Nat Med       Date:  1998-10       Impact factor: 53.440

4.  Large-scale characterization of peptide-MHC binding landscapes with structural simulations.

Authors:  Chen Yanover; Philip Bradley
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-08       Impact factor: 11.205

5.  Optimization of therapeutic proteins to delete T-cell epitopes while maintaining beneficial residue interactions.

Authors:  Andrew S Parker; Karl E Griswold; Chris Bailey-Kellogg
Journal:  J Bioinform Comput Biol       Date:  2011-04       Impact factor: 1.122

6.  Structure-based redesign of proteins for minimal T-cell epitope content.

Authors:  Yoonjoo Choi; Karl E Griswold; Chris Bailey-Kellogg
Journal:  J Comput Chem       Date:  2013-01-08       Impact factor: 3.376

7.  Rationally engineered therapeutic proteins with reduced immunogenicity.

Authors:  Shabnam Tangri; Bianca R Mothé; Julie Eisenbraun; John Sidney; Scott Southwood; Kristen Briggs; John Zinckgraf; Pamuk Bilsel; Mark Newman; Robert Chesnut; Cynthia Licalsi; Alessandro Sette
Journal:  J Immunol       Date:  2005-03-15       Impact factor: 5.422

8.  Optimization algorithms for functional deimmunization of therapeutic proteins.

Authors:  Andrew S Parker; Wei Zheng; Karl E Griswold; Chris Bailey-Kellogg
Journal:  BMC Bioinformatics       Date:  2010-04-09       Impact factor: 3.169

9.  Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.

Authors:  Raffit Hassan; Susie Bullock; Ahalya Premkumar; Robert J Kreitman; Hedy Kindler; Mark C Willingham; Ira Pastan
Journal:  Clin Cancer Res       Date:  2007-09-01       Impact factor: 12.531

10.  The immune epitope database 2.0.

Authors:  Randi Vita; Laura Zarebski; Jason A Greenbaum; Hussein Emami; Ilka Hoof; Nima Salimi; Rohini Damle; Alessandro Sette; Bjoern Peters
Journal:  Nucleic Acids Res       Date:  2009-11-11       Impact factor: 16.971

View more
  40 in total

1.  Adaptive Immunity to Leukemia Is Inhibited by Cross-Reactive Induced Regulatory T Cells.

Authors:  Luke S Manlove; Katherine E Berquam-Vrieze; Kristen E Pauken; Richard T Williams; Marc K Jenkins; Michael A Farrar
Journal:  J Immunol       Date:  2015-09-16       Impact factor: 5.422

2.  BWM*: A Novel, Provable, Ensemble-based Dynamic Programming Algorithm for Sparse Approximations of Computational Protein Design.

Authors:  Jonathan D Jou; Swati Jain; Ivelin S Georgiev; Bruce R Donald
Journal:  J Comput Biol       Date:  2016-01-08       Impact factor: 1.479

3.  Antibody humanization by structure-based computational protein design.

Authors:  Yoonjoo Choi; Casey Hua; Charles L Sentman; Margaret E Ackerman; Chris Bailey-Kellogg
Journal:  MAbs       Date:  2015-08-07       Impact factor: 5.857

4.  Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38.

Authors:  Ronit Mazor; Gilad Kaplan; Dong Park; Youjin Jang; Fred Lee; Robert Kreitman; Ira Pastan
Journal:  Cell Immunol       Date:  2017-01-05       Impact factor: 4.868

5.  Depletion of T cell epitopes in lysostaphin mitigates anti-drug antibody response and enhances antibacterial efficacy in vivo.

Authors:  Hongliang Zhao; Deeptak Verma; Wen Li; Yoonjoo Choi; Christian Ndong; Steven N Fiering; Chris Bailey-Kellogg; Karl E Griswold
Journal:  Chem Biol       Date:  2015-05-21

6.  Massively parallel de novo protein design for targeted therapeutics.

Authors:  Aaron Chevalier; Daniel-Adriano Silva; Gabriel J Rocklin; Derrick R Hicks; Renan Vergara; Patience Murapa; Steffen M Bernard; Lu Zhang; Kwok-Ho Lam; Guorui Yao; Christopher D Bahl; Shin-Ichiro Miyashita; Inna Goreshnik; James T Fuller; Merika T Koday; Cody M Jenkins; Tom Colvin; Lauren Carter; Alan Bohn; Cassie M Bryan; D Alejandro Fernández-Velasco; Lance Stewart; Min Dong; Xuhui Huang; Rongsheng Jin; Ian A Wilson; Deborah H Fuller; David Baker
Journal:  Nature       Date:  2017-09-27       Impact factor: 49.962

7.  Computationally optimized deimmunization libraries yield highly mutated enzymes with low immunogenicity and enhanced activity.

Authors:  Regina S Salvat; Deeptak Verma; Andrew S Parker; Jack R Kirsch; Seth A Brooks; Chris Bailey-Kellogg; Karl E Griswold
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-12       Impact factor: 11.205

8.  Immunosilencing a highly immunogenic protein trimerization domain.

Authors:  Kwinten Sliepen; Thijs van Montfort; Mark Melchers; Gözde Isik; Rogier W Sanders
Journal:  J Biol Chem       Date:  2015-01-29       Impact factor: 5.157

Review 9.  Design and engineering of deimmunized biotherapeutics.

Authors:  Karl E Griswold; Chris Bailey-Kellogg
Journal:  Curr Opin Struct Biol       Date:  2016-06-17       Impact factor: 6.809

10.  Development of a strategy and computational application to select candidate protein analogues with reduced HLA binding and immunogenicity.

Authors:  Sandeep Kumar Dhanda; Alba Grifoni; John Pham; Kerrie Vaughan; John Sidney; Bjoern Peters; Alessandro Sette
Journal:  Immunology       Date:  2017-09-28       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.